Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4814999 | 0.90 | GRIN1 (0.67) | GRIN1GRIN2B | |
| SCHEMBL8318042 | 0.79 | GRIN1 (1.00) | GRIN1GRIN2B | |
| SCHEMBL13175638 | 0.77 | AKR1C3 (0.64) | — | |
| SCHEMBL4888577 | 0.76 | HRH4 (0.56) | — | |
| SCHEMBL4527497 | 0.75 | GRIN2D (0.61) | GRIN1GRIN2B | |
| SCHEMBL4805201 | 0.71 | GRIN2D (0.80) | GRIN1GRIN2B | |
| SCHEMBL5269544 | 0.71 | GRIN1 (0.84) | GRIN1GRIN2B | |
| SCHEMBL4888808 | 0.71 | GRIN1 (0.51) | GRIN1GRIN2B | |
| SCHEMBL4807651 | 0.71 | GRIN2D (0.57) | GRIN1GRIN2B | |
| SCHEMBL4816084 | 0.71 | GRIN2D (0.57) | GRIN1GRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7378431-B2 | Amide derivatives as NMDA receptor antagonists | RICHTER GEDEON VEGYESZETI GYAR RT. (HU) | 2008-05-27 | — | — | US | claimed |
| US-20050113361-A1 | Amide derivatives as NMDA receptor antagonists | HORVATH CSILLA (HU) | 2005-05-26 | — | — | US | claimed |
| EP-1328514-A1 | AMIDE DERIVATIVES AS NMDA RECEPTOR ANTAGONISTS | RICHTER GEDEON VEGYESZETI GYAR R.T. (HU) | 2003-07-23 | — | — | EP | claimed |
| WO-2002034718-A1 | AMIDE DERIVATIVES AS NMDA RECEPTOR ANTAGONISTS | RICHTER GEDEON VEGYESZETI GYAR RT. (HU) | 2002-05-02 | — | — | WO | claimed |
| US-7378431-B2 | Amide derivatives as NMDA receptor antagonists | RICHTER GEDEON VEGYESZETI GYAR RT. (HU) | 2008-05-27 | — | — | US | disclosed |
| US-7375116-B2 | Amide derivatives as NMDA receptor antagonists | RICHTER GEDEON VEGYESZETI GYAR RT. (HU) | 2008-05-20 | — | — | US | disclosed |
| US-7365083-B2 | Amide derivatives as NMDA receptor antagonists | RICHTER GEDEON VEGYESZETI GYAR RT. (HU) | 2008-04-29 | — | — | US | disclosed |
| US-7361670-B2 | Amide derivatives as NMDA receptor antagonists | RICHTER GEDEON VEGYESZETI GYAR RT. (HU) | 2008-04-22 | — | — | US | disclosed |
| US-20050159451-A1 | Amide derivatives as NMDA receptor antagonists | HORVATH CSILLA (HU) | 2005-07-21 | — | — | US | disclosed |
| US-6919355-B2 | Amide derivatives as NMDA receptor antagonists | RICHTER GEDEON VEGYESZETI GYAR RT. (HU) | 2005-07-19 | — | — | US | disclosed |
| US-20050113359-A1 | Amide derivatives as NMDA receptor antagonists | HORVATH CSILLA (HU) | 2005-05-26 | — | — | US | disclosed |
| US-20050113361-A1 | Amide derivatives as NMDA receptor antagonists | HORVATH CSILLA (HU) | 2005-05-26 | — | — | US | disclosed |
| US-20050113360-A1 | Amide derivatives as NMDA receptor antagonists | HORVATH CSILLA (HU) | 2005-05-26 | — | — | US | disclosed |
| US-20030199552-A1 | Amide derivatives as NMDA receptor antagonists | RICHTER GEDEON VEGYESZETI GYAR RT. | 2003-10-23 | — | — | US | disclosed |
| EP-1328514-A1 | AMIDE DERIVATIVES AS NMDA RECEPTOR ANTAGONISTS | RICHTER GEDEON VEGYESZETI GYAR R.T. (HU) | 2003-07-23 | — | — | EP | disclosed |
| WO-2002034718-A1 | AMIDE DERIVATIVES AS NMDA RECEPTOR ANTAGONISTS | RICHTER GEDEON VEGYESZETI GYAR RT. (HU) | 2002-05-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050113361-A1 | Amide derivatives as NMDA receptor antagonists | GRIN1, GRIN3A, GRIN2B | GRIN1 1/4885GRIN2B 3/4885 |
| US-20050113360-A1 | Amide derivatives as NMDA receptor antagonists | GRIN1, GRIN3A, GRIN2B | GRIN1 1/4885GRIN2B 3/4885 |
| US-20050159451-A1 | Amide derivatives as NMDA receptor antagonists | GRIN1, GRIN3A, GRIN2B | GRIN1 1/4885GRIN2B 3/4885 |
| US-20050113359-A1 | Amide derivatives as NMDA receptor antagonists | GRIN1, GRIN3A, GRIN2B | GRIN1 1/4885GRIN2B 3/4885 |
| US-20030199552-A1 | Amide derivatives as NMDA receptor antagonists | GRIN1, GRIN3A, GRIN2C | GRIN1 1/4885GRIN2B 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.